Injectafer (Ferric Carboxymaltose) Patent Expiration, LOE Window & CMS Spending

Injectafer (Ferric Carboxymaltose) by Daiichi Sankyo: FDA Orange Book core substance LOE 2027-02-05 (last listed 2028-02-15), 0 AB generics, $41.2M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDaiichi Sankyo
FDA Application & PathwayN203565 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-02-05
Last Listed Patent or Exclusivity Date2028-02-15
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$41.2M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$41.2M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 26.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.